Diagnostic Firm diaDexus Awaits Possible Boom from Glaxo Trials

10/24/13Follow @tanseyverse

Medical researchers often find tantalizing hints about the causes of disease when they spot biomolecules that seem to be closely associated with the onset of an illness—like the amyloid plaques seen in the brains of people with Alzheimer’s disease. Pharmaceutical companies often run with those hints, creating experimental drugs targeted at those suspect biomolecules.

But are the suspect disease markers actually causing the illness, or are they just incidental symptoms or byproducts of it?  Will a drug targeting a disease marker do anything to combat the disease?

For a biomarker called Lp-PLA2 that’s long been associated with heart attack risk, answers to that question will start coming by the end of this year, when UK-based GlaxoSmithKline releases initial results from the first of two huge late-stage clinical trials of its experimental drug darapladib. Darapladib inhibits the action of the Lp-PLA2 enzyme, whose full name is lipoprotein-associated phospholipase A2.

It’s not clear yet whether high Lp-PLA2 levels in the bloodstream cause heart attacks and strokes, or are merely a warning sign that one might be impending. But if darapladib staves off these events in people with hardening of the arteries, Glaxo could have an international blockbuster drug on its hands. And a success for Glaxo could also be a bonanza for the small South San Francisco company diaDexus. Nearly all of diaDexus’s revenues come from the sale of a single product: a diagnostic test for heightened levels of Lp-PLA2.

At low levels, the enzyme has a normal, beneficial function in healthy people—it scavenges cholesterol from the walls of arteries and helps clear it out, says diaDexus CEO Brian Ward.

diaDexus CEO Brian Ward

diaDexus CEO Brian Ward

“You need a little bit of it,” Ward says. But a build-up of Lp-PLA2 is a danger sign that hardened deposits of plaque in the arteries are more likely to break apart, sending clots into the vessels that could cut off the blood supply to parts of the heart or brain.

Physicians use the diaDexus test, called PLAC, to find out how likely it is that their patients who have a few risk factors for cardiovascular disease, such as age or high blood pressure, will actually suffer a heart attack or stroke. This can happen even in patients with low cholesterol, Ward says.

“We save lives because we uncover the hidden risk,” Ward says. Medicare, and about 50 percent of private insurers, reimburse for the diaDexus test in its role as a mere signal of developing danger that may stem from causes other than the Lp-PLA2 marker itself.

But if Glaxo’s trials show that blocking the activity of Lp-PLA2 fends off a cardiovascular crisis, Ward says, the enzyme could be redefined as a risk factor in itself.  This could help diaDexus overcome remaining reimbursement barriers for the PLAC test, and spur physicians to order it, he says. The test could also become the companion diagnostic to identify patients who might benefit from Glaxo’s darapladib.

Since its founding in 1999, the fortunes of diaDexus have been intertwined with the big pharmaceutical company’s. DiaDexus was formed as a joint project of Incyte Pharmaceuticals and SmithKline Beecham, which merged with GlaxoWellcome to form GlaxoSmithKline in 2001. From SmithKline Beecham, diaDexus received exclusive rights to develop a diagnostic test for Lp-PLA2.  DiaDexus earned FDA clearance to market its test in 2003 for heart disease risk and in 2005 for the risk of stroke.

The test was designed to alert doctors when an unseen process was beginning to raise the cardiovascular risk of patients who have never suffered heart disease or stroke. When people develop plaque deposits in their arteries, these buildups can remain stable for a time under a hardened “cap.”  But the deposits can later become inflamed, unstable, and prone to rupture. An increase in Lp-PLA2 levels is associated with that inflammatory  process, Ward says.

Doctors can now order the test as part of an advanced lipid profile for patients who already have two or more risk factors, including family history, excess weight, diabetes, age over 50, high cholesterol, and smoking. DiaDexus estimates that about 85 million adults in the United States have two or more of these risk factors. If  Lp-PLA2 levels are high, physicians may decide to start treatment with statin drugs or other treatments, Ward says. Heart attack and stroke are among the top causes of death in the United States.

However, the financial road has been rocky for diaDexus, which was … Next Page »

Bernadette Tansey is a freelance journalist based in Berkeley, CA. Follow @tanseyverse

Single Page Currently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

  • Mad_Scientist

    It’s usually the very desperate companies who take a drug into phase 3 after it failed phase 2. Almost guarantee for failure in phase 3. I guess GSK has nothing better to do with its money?